RT Journal Article
SR Electronic
T1 Complete remission in a patient with widely metastatic HER2-amplified pancreatic adenocarcinoma following multimodal therapy informed by tumor sequencing and organoid profiling
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.16.21267326
DO 10.1101/2021.12.16.21267326
A1 King, Daniel A
A1 Smith, Amber R
A1 Pineda, Gino
A1 Nakano, Michitaka
A1 Michelini, Flavia
A1 Goedegebuure, S. Peter
A1 Thyparambil, Sheeno
A1 Liao, Wei-Li
A1 McCormick, Aaron
A1 Ju, Jihang
A1 Cioffi, Michele
A1 Zhang, Xiuli
A1 Hundal, Jasreet
A1 Griffith, Malachi
A1 Grandori, Carla
A1 Pollastro, Maddy
A1 Rosati, Rachele
A1 Margossian, Astrid
A1 Chatterjee, Payel
A1 Ainge, Trevor
A1 Flory, Marta
A1 Ocampo, Paolo
A1 Chen, Lee-may
A1 Poultsides, George A
A1 Baron, Ari D
A1 Chang, Daniel T
A1 Herman, Joseph M
A1 Gillanders, William E
A1 Park, Haeseong
A1 Hoos, William A
A1 Nichols, Mike
A1 Fisher, George A
A1 Kuo, Calvin J
YR 2021
UL http://medrxiv.org/content/early/2021/12/21/2021.12.16.21267326.abstract
AB Here, we demonstrate a complete clinical response achieved in a patient with HER2+ metastatic pancreatic ductal adenocarcinoma to a coordinated barrage of anti-HER2, personalized vaccine and checkpoint inhibition immunotherapy, radiation, and chemotherapy. Comprehensive organoid profiling with drug sensitivity screening and drug testing suggested a vulnerability to anti-HER2 directed therapy, facilitating personalized treatment selection for our patient, which contributed to her clinical benefit. Immune response monitoring following personalized vaccine, radiation and checkpoint inhibition showed a sustained increase in neoantigen specific T cell response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe investigators are indebted to our patient for the permission to publish her clinical story. Informed consent to publish information and/or images from the patient. We appreciate guidance from Maurizio Scaltriti for several organoid analyses. Drs. Sunil Hingorani, Andrew Hendifar, and Ted Hong provided valuable clinical insight. We are grateful to Kevin White, Greg Call, Nike Beaubier, and Amber Solari, at Tempus for sharing HER2 distribution data for research use. We are grateful for support from the NIH (U01CA217851, U54CA224081, R01CA2515143), Seed Grant from the Stanford Cancer Institute, NIH NCI Award (U01CA248235), and V Scholar Award from the V Foundation for Cancer Research (V2018-007).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Northwell Health name waived ethical approval for this work. No PHI data are disclosed.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript, data are available upon reasonable request for purpose of peer review.